Mazen Juratli- Medicine- Outstanding Scientist Award

Posted on by Leave a Comment on Mazen Juratli- Medicine- Outstanding Scientist Award

Mazen Juratli- Medicine- Outstanding Scientist Award

Prof. Mazen Juratli distinguished academic and researcher in the field Medicine. He is a dedicated and accomplished Assistant Professor and Senior Consultant Surgeon with a strong background in General, Visceral, and Transplant Surgery, specializing in upper GI tumors, reflux surgery, and peritoneal carcinomatosis. His experience encompasses both the clinical and research facets of surgical oncology, demonstrating a steadfast dedication to advancing medical science and enhancing patient care. He is actively pursuing opportunities to make substantial contributions to the field of surgery and academic medicine, particularly in the realm of Upper GI and peritoneal carcinomatosis surgery, along with related areas.

🌐 Professional Profile

Educations📚📚📚

He earned his Ph.D. in Interdisciplinary Biomedical Science (IBS) from the Arkansas Nanomedicine Center at the University of Arkansas for Medical Sciences (UAMS) in Little Rock, AR, USA, completing his studies between January 2012 and May 2014. Prior to that, he attended medical school at Philipps University in Marburg, Germany, from October 2003 to November 2009.

 Experience:

He is currently an Assistant Professor and Senior Consultant Surgeon at the University Hospital of Muenster in Muenster, Germany, within the Department of Generalhttps://networkscience-conferences.researchw.com/?p=33910&preview=true, Visceral, and Transplant Surgery. He specializes as an Upper Gastrointestinal (GI) Surgeon, adept in robotic, minimally invasive, and open surgeries. Additionally, he heads the Stomach Cancer and Peritoneal Carcinomatosis Surgical Center, serves as Deputy Head of the Esophagus Cancer Center, and leads the Surgical Biobank. He is also the Principal Investigator (PI) for the Liquid Biopsy Research Group. His licensure and certifications include being a Senior Explant Surgeon for Donor Surgery: Liver and Kidney (since October 2023) and a Certified Center Surgeon for the Upper GI Tract (since January 2023). He is a member of the Board of Directors of the Interdisciplinary Working Group for Clinical Hemotherapy (IAKH e.V.) and holds an additional qualification in Specialized Visceral Surgery (Zusatzbezeichnung Spezielle Viszeralchirurgie) from the Ärztekammer Westfalen-Lippe, Germany, since September 2022. He became a Fellow of the European Board of Surgery (F.E.B.S.) in Surgical Oncology in September 2022 and has been an Assistant Professor (Privatdozent Dr. med. habil.) since January 2021. He has served as a Senior Consultant Surgeon (Oberarzt) in the Department of General, Visceral, and Transplant Surgery at the University Hospital of Muenster since September 2020. He obtained his German Board Certification in Visceral Surgery – Consultant Surgeon (Facharzt) from the Ärztekammer Hessen, Germany, in June 2019. He earned his Ph.D. from the University of Arkansas for Medical Sciences (UAMS) in Little Rock, AR, USA, in December 2014 and his Doctor of Medicine (Dr. med.) from Philipps University in Marburg, Germany, in December 2009, where he also obtained his German Federal License (Approbation) in November 2009.

Awards, Grants and Honors

He has received numerous awards, grants, and honors throughout his career. In 2024, he secured industrial grant funding from Johnson & Johnson for a project on surgical smoke exposure investigation in surgical safety, amounting to €169,681, and also received the German Society for General and Visceral Surgery (DGAV) Travel Award, valued at €5000. He earned abstract prizes for his pilot studies on diagnostic and prognostic tumor markers in adenocarcinomas of the gastroesophageal junction and extracellular vesicles as potential biomarkers for hepatocellular carcinoma, presented at Visceral Medicine 2023 in Hamburg and NRW-Visceral Medicine 2023 in Essen, each prize valued at €500. In 2022, he won another abstract prize for his work on the long-term effects of liver resection on circulating stem cells in hepatocellular carcinoma, presented at Visceral Medicine in Hamburg. He was recognized as a Medical Scientist by the Else Kröner-Forschungskolleg (EKFK) in 2018 and received a grant of €15,000 from the B. Braun-Stiftung the same year. In 2017, he was awarded €66,000 for young talent promotion by Frankfurt Research Promotion at Goethe University, Frankfurt am Main, Germany. His achievements also include the Frankfurt Research Prize of the Rudolf Geißendörfer Foundation in 2015, valued at €5,000, and a poster prize at the 19 Chirurgische Forschungstage in Würzburg, Germany, in 2015, valued at €500. He received the second prize for the Cancers Best Paper Award in 2015 and the German Academic International Network (GAIN) Travel Award to attend the 18th European Career Fair (ECF) in Boston, MA, USA, in 2014, valued at €2,000. He was honored with the People’s Choice award for Science as Art at the Nanotechnology for Health Care Conference in Petit Jean, AR, USA, in 2014. Additionally, he was granted $78,000 by the Arkansas Breast Cancer Research Program (ABCRP) in 2013 and received €50,000 from the DFG – German Research Foundation in 2012.

 

📝🔬Publications📝🔬

  • Jens Hoelzen, Lukas Fortmann, Dhruvajyoti Roy, Carsten Szardenings, Martina Holstein, Ann-Kathrin Eichelmann,Emile Rijcken,Brooke E. Frankauer, Peter Barth, Eva Wardelmann, Andreas Pascher, and Mazen A. Juratli. Robotic-Assisted Esophagectomy with Total Mesoesophageal Excision EnhancesR0-Resection in Patients with Esophageal Cancer – a single-center experience. Surgery 05/2024. In Press
  • Lamberty SA, Hoelzen JP, Katou S, Becker F, Juratli MA, Andreou A, Morgül MH, Pascher A, Strücker B. Validation of the IWATE Criteria in Robotic-Assisted Liver Resections. J Clin Med. 2024 May 3;13(9):2697. doi: 10.3390/jcm13092697. PMID: 38731226; PMCID: PMC11084793.
  • Juratli, M.A., Pollmann, N.S., Oppermann, E. et al. Extracellular vesicles as potential biomarkers for diagnosis and recurrence detection of hepatocellular carcinoma. Sci Rep 14, 5322 (2024). https://doi.org/10.1038/s41598-024-55888-8.
  • Diedrich AM, Daneshgar A, Tang P, Klein O, Mohr A, Onwuegbuchulam OA, von Rueden S, Menck K, Bleckmann A, Juratli MA, Becker F, Sauer IM, Hillebrandt KH, Pascher A, Struecker B. Proteomic analysis of decellularized mice liver and kidney extracellular matrices. J Biol Eng. 2024 Feb 22;18(1):17. doi: 10.1186/s13036-024-00413-8. PMID: 38389090; PMCID: PMC10885605
  • de Jongh C, Cianchi F, Kinoshita T, Kingma F, Piccoli M, Dubecz A, Kouwenhoven E, van Det M, Mala T, Coratti A, Ubiali P, Turner P, Kish P, Borghi F, Immanuel A, Nilsson M, Rouvelas I, Hӧlzen JP, Rouanet P, Saint-Marc O, Dussart D, Patriti A, Bazzocchi F, van Etten B, Haveman JW, DePrizio M, Sabino F, Viola M, Berlth F, Grimminger PP, Roviello F, van Hillegersberg R, Ruurda J; UGIRA Collaborative Group. Surgical Techniques and Related Perioperative Outcomes After Robot-assisted Minimally Invasive Gastrectomy (RAMIG): Results From the Prospective Multicenter International Ugira Gastric Registry. Ann Surg. 2023 Nov 3. doi: 10.1097/SLA.0000000000006147. Epub ahead of print. PMID: 37922237.
  • Hoelzen JP, Frankauer BE, Szardenings C, Roy D, Pollmann L, Fortmann L, Merten J, Rijcken E, Juratli MA, Pascher A. Reducing the Risks of Esophagectomies: A Retrospective Comparison of Hybrid versus Full-Robotic-Assisted Minimally Invasive Esophagectomy (RAMIE) Approaches. J Clin Med. 2023 Sep 7;12(18):5823. doi: 10.3390/jcm12185823. PMID: 37762765; PMCID: PMC10531670.Two senior authors
  • Peters AK, Juratli MA, Roy D, Merten J, Fortmann L, Pascher A, Hoelzen JP. Factors Influencing Postoperative Complications Following Minimally Invasive Ivor Lewis Esophagectomy: A Retrospective Cohort Study. J Clin Med. 2023 Aug 31;12(17):5688. doi: 10.3390/jcm12175688. PMID: 37685756; PMCID: PMC10488704.Contributed equally to the study
  • Mohr A, Besser M, Broichhausen S, Winter M, Bungert AD, Strücker B, Juratli MA,Pascher A, Becker F. The Influence of Apremilast-Induced Macrophage Polarization on Intestinal Wound Healing. J Clin Med. 2023 May 9;12(10):3359. doi: 10.3390/jcm12103359. PMID: 37240465; PMCID: PMC10219563

Miguel Angel Rodríguez Cabello -Medicine and Health Sciences – Best Researcher Award

Posted on by Leave a Comment on Miguel Angel Rodríguez Cabello -Medicine and Health Sciences – Best Researcher Award

Miguel Angel Rodríguez Cabello -Medicine and Health Sciences – Best Researcher Award

Dr. Miguel Angel Rodríguez Cabello distinguished academic and researcher in the field Medicine and Health Sciences. He completed several postgraduate programmes at CEU and Cardenal Herrera University from October 2018 to July 2019, including expertise in Medical Direction and Health Services Management, Medical Direction and Management of Clinical Units, Quality Medical Management, and Leadership and Directing Skills in Health. Additionally, he earned a Certificate of Da Vinci System Training as a Console Surgeon on 16th October 2017, at EU Direct: IRCAD in Strasbourg, France. Currently, he is pursuing a Master’s Degree in Clinical, Medical, and Assistance Management at CEU and Cardenal Herrera University. He participated in the Salzburg ESU Weill Cornell Seminar in Masterclass in Urology in Salzburg, Austria, from 9th to 15th July 2017, earning 37 DFP credits from the Austrian Chamber of Physicians. He is a member of EU-ACME, the European Board of Urology (EBU), and the European Association of Urology (EAU).

He completed a hands-on training course on Laparoscopy and Endourology, accredited by the European Accreditation Council for Continuing Medical Education, earning 24 European CME credits from 31st January to 3rd February 2017 in Cáceres, Spain. He also participated in the European Training in Basic Laparoscopic Urological Skills (E-BLUS) on 13th March 2016 at the 31st Annual Congress of the European Association of Urology in Munich, Germany, under Dr. J. Palou. He became a Fellow of the European Board of Urology (F.E.B.U.) after passing the EBU Written Examination on 14th November 2014 with a qualification of 8, and the EBU Oral Examination on 6th June 2015 in Brussels, Belgium, with a successful qualification of 7/9.

He completed a postgraduate programme on expertise in Urological Ultrasound at the University of Zaragoza during the VI Course 2015–2016. He holds a Diploma in Design and Statistics and a Master’s Degree in Research Methodology from Universidad Autónoma de Barcelona (Spain). Additionally, he completed a postgraduate programme on expertise in Statistics Applied to Health Sciences at UNED during the 2012-2013 academic year, earning an outstanding qualification and 20 ECTS credits (500 hours).

🌐 Professional Profile

Educations📚📚📚

He holds a PhD in Medicine and Surgery from Universidad Autónoma de Madrid, awarded on 9th June 2023, with his thesis receiving an Outstanding qualification with Cum Laude mention by unanimity. He also earned two Postgraduate Diplomas in 2023 from Universidad Autónoma de Barcelona: one in Systematic Review of Studies: Meta-Analysis and Evaluation Tests, and another in Systematic Review of Studies: Synthesis of Information. In March 2023, he completed the Aquablation Therapy Training Programme, receiving a Certificate of Completion from Procept BioRobotics. He holds a Master’s Degree in Research Methodology: Design and Statistics in Health Sciences from Universidad Autónoma de Barcelona, which he completed between 2017 and 2021. Additionally, he completed the Rezūm Procedure Healthcare Practitioner Training in August 2020, acknowledged by Boston Scientific. His academic achievements also include a Diploma in Design and Statistics and a Master in Research Methodology from Universidad Autónoma de Barcelona, obtained between 2016 and 2020. Furthermore, he holds a Master’s Degree in Clinical, Medical, and Care Management.

 

Work Experience

He has been working as a Physician Specialist in Urology at University Hospital La Moraleja in Madrid since May 2015 and as a Physician Specialist in Urology and Infertility at OVOCLINIC in Madrid since September 2021. Previously, he was a resident at the Urology Department of University Hospital Ramón y Cajal in Madrid, Spain, from May 2010 to May 2015, and worked as a General Physician at Company Medycsa, Calle Valentín Beato 5, Madrid, between 2009 and 2010. He completed a Fellowship in Laparoscopic and Robotic Urological Surgery at Saint Augustin Clinic, Bordeaux (France) from September to November 2014 and participated in the Salzburg ESU Weill Cornell Seminar in Masterclass in Urology, organised by the European Association of Urology, European School of Urology (ESU), and Weill Cornell Medicine, earning 37 DFP credits from the Austrian Chamber of Physicians in Salzburg, Austria, from 9th to 15th July 2017. From 2010 to 2014, he was a Professor of Urology at CTO Medicina, delivering 180 hours of lectures under the direction of Dr. Roberto Garcia Leal. He supervised residents during their incorporation into the Department of Urology and provided education and oversight to students of the Medicine Degree at Universidad Francisco de Vitoria as well as to residents of Gynecology.

From 2020 to 9th June 2023, he was a Ph.D. student in Medicine and Surgery at Universidad Autónoma de Madrid, where he studied the diagnostic validity of predictive models in prostate cancer using the Prostate Imaging and Data Reporting System version 2 (PIRADSv2) and PSA density. Since 2023, he has been the principal investigator of a randomised, double-blind, placebo-controlled study evaluating the effect of a probiotic on urinary tract microbiota in women with recurrent urinary tract infections (rUTI), study code IC-HULM-007-23, known as the PROBUTI study. Since 2021, he has been an independent technical evaluator of research projects, R+D+I, and technological innovation. He is currently the principal investigator in the Prostate Imaging using MRI +/- contrast Enhancement (PRIME) study at University College London (UCL), which assesses whether bi-parametric MRI is non-inferior to multi-parametric MRI in diagnosing clinically significant prostate cancer. Additionally, he actively collaborates as the principal investigator in the phase 3 clinical trial E.mbrace Amendment 2 VAC52416 (JNJ-78901563 [ExPEC9V]), a study aimed at assessing the efficacy, safety, and immunogenicity of vaccination with ExPEC9V in preventing invasive extraintestinal pathogenic Escherichia coli disease in adults aged 60 years and older with a history of urinary tract infection in the past two years.

His ongoing research projects include a comparative study between multiparametric magnetic resonance systems of 1.5 and 3 Teslas using the PIRADS version 2 classification in the diagnosis of prostate cancer (registered under number 40/2021); a cross-sectional study of PSA density assessment and multiparametric resonance as predictors of prostate cancer (registered under number 39/2021); and the evaluation of the Oncotype Dx genetic test in therapeutic decisions for low-risk prostate cancer, a multicenter study (registered under number 29/2021). From 2020 to the present, he has been conducting research on predictive models and validation of diagnostic tests in prostate cancer, focusing on multiparametric prostate MRI and fusion prostate biopsy as part of his PhD at Universidad Autónoma de Madrid. Between 2018 and 2019, he actively collaborated in the RITUMAN study, a multicenter and coordinated study on the management of patients with recurrent urinary tract infections. From 2016 to 2017, he contributed to the PREVENT-LIT study, which focused on the management of patients with urolithiasis. From 2011 to 2013, he participated in the EMPARO-CU study, a multicenter and coordinated study examining the care process and outcomes in a cohort of patients diagnosed with urological cancer (bladder and prostate).

 

📝🔬Publications📝🔬
  • Giganti F, Ng A, Asif A, Chan VW, Rossiter M, Nathan A, Khetrapal P, Dickinson L,
    Punwani S, Brew-Graves C, Freeman A, Emberton M, Moore CM, Allen C,
    Kasivisvanathan V; PRIME Quality Improvement Group. Global Variation in Magnetic
    Resonance Imaging Quality of the Prostate. Radiology. 2023 Oct;309(1):e231130. doi:
    10.1148/radiol.231130. PMID: 37815448. Contributor.
  • Miguel Angel Rodríguez Cabello, Santiago Méndez Rubio, Juan Luis Sanz Miguelañez,
    Alvaro Moraga Sanz, Carolina Aulló González, Arturo Platas Sancho. Prevalence and
    grade of malignancy differences with respect to the area of involvement in
    Curriculum Vitae
    Miguel Ángel Rodríguez Cabello
    5
    multiparametric resonance imaging of the prostate in the diagnosis of prostate
    cancer using the PI-RADS version 2 classification. World J Urol. 2023 May 30. DOI:
    10.1007/s00345-023-04466-0.
  • Cabello, R., Mendez Rubio, S., Sanz Miguelanez, J. L., Vazquez Alba, D., Moraga Sanz, A.,
    & Platas Sancho, A. (2023, February). The importance of the location of the PI-RADS
    lesion within the prostate as a predictive variable of malignant degree. In EUROPEAN
    UROLOGY (Vol. 83, pp. S432-S432). RADARWEG 29, 1043 NX AMSTERDAM,
    NETHERLANDS: ELSEVIER.
  • Rodríguez Cabello MA, Méndez Rubio S, Platas Sancho A, Carballido Rodríguez J.
    Diagnostic evaluation and incorporation of PSA density and the prostate imaging
    and data reporting system (PIRADS) version 2 classification in risk-nomograms for
    prostate cancer. World J Urol. 2022 Oct;40(10):2439-2450. doi: 10.1007/s00345-022-
    04118-9. Epub 2022 Aug 8. PMID: 35941245.
  • Rodríguez Cabello, M.A., Méndez Rubio, S., Moraga Sanz, A., Sanz Miguelañez, J.L.,
    Vázquez Alba, D., Aulló González, C., Platas Sancho, A. Comparative study between
    1.5 and 3 Tesla multiparametric magnetic resonance imaging systems using the
    PIRADS version 2 classification in the diagnosis of prostate cancer. Arch-Esp-Urol
    2022;75(4):330–8.
  • Garrido-Abad P, Rodriguez-Cabello MÁ, Platas-Sancho A. Steinstrasse following
    extracorporeal shock wave lithotripsy. Arch Esp Urol. abril de 2021;74(3):363-4.
    PMID: 33818435.